BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 23353886)

  • 1. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours.
    Sharma P; Jain TK; Parida GK; Karunanithi S; Patel C; Sharma A; Thulkar S; Julka PK; Bal C; Kumar R
    Br J Radiol; 2014 Aug; 87(1040):20140263. PubMed ID: 24896199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of neck node status using 18F-FDG PET for salivary duct carcinoma of the major salivary glands.
    Kim JY; Lee SW; Kim JS; Kim SY; Nam SY; Choi SH; Roh JL; Choi EK; Kim JH; Song SY; Yoon SM; Kim YS; Kim SS; Park JH; Shin HS; Chang SK; Ahn SD
    J Nucl Med; 2012 Jun; 53(6):881-6. PubMed ID: 22573820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of 18F-FDG PET for patients with salivary gland malignancies.
    Roh JL; Ryu CH; Choi SH; Kim JS; Lee JH; Cho KJ; Nam SY; Kim SY
    J Nucl Med; 2007 Feb; 48(2):240-6. PubMed ID: 17268021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
    Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
    Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.
    Sharma P; Jain S; Karunanithi S; Pal S; Julka PK; Thulkar S; Malhotra A; Bal C; Kumar R
    Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1084-92. PubMed ID: 24435775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of FDG-PET in the management of patients with salivary gland malignancy.
    Otsuka H; Graham MM; Kogame M; Nishitani H
    Ann Nucl Med; 2005 Dec; 19(8):691-4. PubMed ID: 16444995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.